1. The first 100Experience with Mediphacos MF-R2 IOL from a privatepractice in Denmark.

2. Financial affiliation I do not receive any financial support from any of theproducers mentioned in this paper. 3. Viborg Eyeclinic 4. Viborg Eyeclinic Private clinic, public remuneration for operations. +- 800 lens operations per year. Lasercenter, excimer 1 ophthalmic surgeon, one cosmetic surgeon, 2optometrists 5. Incitament for IOL change Danish government demands: Hydrophobic IOL Asphaeric optics Foldable IOL Acrylic material 360 square edge 6. My situation Prefer to not make wound assisted injections Prefer to inject the IOL into the capsule More controlled Not possible with the new demands from thegovernment and the existing IOLs in Denmark Needed to find a new hydrophobic IOL that could gointo the eye through my 2,2 mm incision. 7. My requirements The ideal IOL material must provide retinal protectionand combine positive features of hydrophobic andhydrophilic acrylics. Has to go thrugh a 1.8 mm tip Not a new material 8. FlexacrylMediphacos A unique copolymerthat combineshydrophobic andhydrophilic monomers.Its not a coatedhydrophilic IOL. 9. MiniflexFlexacryl IOLs Conventional S-shaped single piece Also a preloaded version MFR Implantation improved plate hapticdesign 10. Comparation I used both of them for a couple of months When injected through the same 1,8 mm tip, the MRFhad the least resistance in my hands. MRF is superior to Microflex as to ease of injection. I felt it was safe to inject the MRF via a 1,8 tip. So I just started doing it 11. Easy implantation 12. Operation Same surgeon Pre-op : Full examination incl. high resolution OCT,biometry with Haag Streit Lenstar. Alcon Infinity, single 2,2 mm incision technique, pre-chop. Post.op. Tobradex [Alcon](Tobramycin +dexamethasone) x3/day for 2 weeks+ Yellox[Bausch&Lomb] (Bromfenac) x 2/day for 6 weeks. 13. Follow up 1 week; BCVA, IOP and slitlamp 1 month; BCVA, IOP, slitlamp + Lenstar Not started yet: 6 months: BCVA, IOP, contrast, slitlamp + Lenstar 14. The first 89 eyes 1 severe post.op. sterile uveitis (woman 58 yo) Resolved with triamcinalone intracameral. Visual aquity of 1,0 s.c. today 1 post.op. CME, male 77 yo. Treated acc. to ESCRS protocol BCVA of 0.8 today No complications with injection procedure No problems with IOL placement in the eye. No physical damage to IOL to be seen 28D IOL the highest diopter injected no problems. 15. Result 76 patient with BCVA minimum 1,0 in the operatedeye (all 5 letters on the Snellen chart 1,0) 8 patients with BCVA from 0,8 to 1,0 2 patients with BCVA from 0,5 to 0.80 (AMD) 1 patient with BCVA 0.4 (ERF) 1 patient with BCVA 0.15 (AMD) 1 patient with BCVA movement of the IOL? 19. Hyperopisation Aaren OptiVis, some few IOLs tended to go towardsthe plus side with D per half year. Slitlamp shows capsular contraction Forces the optic in a posterior direction and bendsthe haptic up toward the pupil. YAG with limited effect. According to Medicophacos, this has not been seenwith the MRF 20. The Alta studyStarts in January 2015MRF / Alcon AcrySof IQ implanted in200 patientsCataract, no co-existing ophtalmicpathology.1 year follow up.VA, IOP, contrast, OCT and LenstarHow does the lens compared to theAcrySof as to standard measuredoutcome? How stable is the IOLcompared to the AcrySof?